Immuneering Corporation (IMRX)
$9.9
-0.36 (-3.51%)
Rating:
Recommendation:
-
| Symbol | IMRX |
|---|---|
| Price | $9.9 |
| Beta | 0.000 |
| Volume Avg. | 0.08M |
| Market Cap | 289.562M |
| Shares () | - |
| 52 Week Range | 3.7-16.167 |
| 1y Target Est | - |
| DCF Unlevered | IMRX DCF -> | |
|---|---|---|
| DCF Levered | IMRX LDCF -> | |
| ROE | -39.67% | Strong Sell |
| ROA | -41.28% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 11.39% | Neutral |
| P/E | -4.25 | Strong Sell |
| P/B | 2.38 | Strong Buy |
Latest IMRX news
About
Download (Excel)Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
Healthcare
Biotechnology
NASDAQ Global Market
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.